Interactions of metoclopramide and ergotamine with human 5-HT3A receptors and human 5-HT reuptake carriers

Authors

  • Jan Walkembach,

    1. Klinik und Poliklinik für Anästhesiologie und operative Intensivmedizin, Universitätskliniken Bonn, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany
    Search for more papers by this author
  • Michael Brüss,

    1. Institut für Pharmakologie und Toxikologie, Universität Bonn, Reuterstr. 2 b, D-53113 Bonn, Germany
    Search for more papers by this author
  • Bernd W Urban,

    1. Klinik und Poliklinik für Anästhesiologie und operative Intensivmedizin, Universitätskliniken Bonn, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany
    Search for more papers by this author
  • Martin Barann

    Corresponding author
    1. Klinik und Poliklinik für Anästhesiologie und operative Intensivmedizin, Universitätskliniken Bonn, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany
    2. Institut für Pharmakologie und Toxikologie, Universität Bonn, Reuterstr. 2 b, D-53113 Bonn, Germany
    Search for more papers by this author

Klinik und Poliklinik für Anästhesiologie und operative Intensivmedizin, Universitätskliniken Bonn, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany. E-mail: martin.barann@ukb.uni-bonn.de

Abstract

  • The actions of metoclopramide and ergotamine, drugs which are used as a combined migraine medication, on human (h)5-HT3A receptors and 5-HT reuptake carriers, stably expressed in HEK-293 cells, were studied with patch-clamp- and ([3H]5-HT)-uptake techniques.

  • At clinical concentrations, metoclopramide inhibited peak and integrated currents through h5-HT3A receptors concentration-dependently (IC50=0.064 and 0.076 μM, respectively) when it was applied in equilibrium (60 s before and during 5-HT (30 μM) exposure). The onset and offset time constants of metoclopramide action were 1.3 and 2.1 s, respectively. The potency of metoclopramide when exclusively applied during the agonist pulse decreased more than 200-fold (IC50=19.0 μM, peak current suppression).

  • Metoclopramide (0.10 μM) did not alter the EC50 of 5-HT-induced peak currents. In contrast to the lack of competitive interaction between metoclopramide and 5-HT in this functional assay, metoclopramide inhibited specific [3H]GR65630 binding to human h5-HT3A receptors in a surmountable manner. This seeming discrepancy between functional studies and radioligand binding experiments may be accounted for by (1) the slow kinetics of inhibition of peak currents by metoclopramide compared with the fast onset and offset kinetics of 5-HT-induced currents and (2) the low efficacy of metoclopramide in inhibiting radioligand binding (e.g. only 20% binding inhibition compared to 79% peak current suppression by 200 nM metoclopramide).

  • At low concentrations (1–10 nM), ergotamine had no effect on 5-HT (30 μM)-induced peak currents. Above clinical concentrations, ergotamine (>3 μM) inhibited them.

  • When both drugs were applied together (0.10 μM metoclopramide+0.001 to 0.01 μM ergotamine), an inhibition of both, peak and integrated current responses was observed.

  • Neither metoclopramide (leqslant R: less-than-or-eq, slant30 μM) nor ergotamine (leqslant R: less-than-or-eq, slant30 μM) had an effect on the 5-HT reuptake carrier as they did not alter the citalopram-sensitive [3H]5-HT uptake.

British Journal of Pharmacology (2005) 146, 543–552. doi:10.1038/sj.bjp.0706351

Ancillary